Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 17,843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Patient Control Clear all

Conditions: Idiopathic Pulmonary Fibrosis, Gastroesophageal Reflux
Interventions: Surgery; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Lymphoma
Interventions: Aprepitant, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab, Ondansetron; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
Interventions: Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Ustekinumab; Drug · Other · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Duarte, California • Tampa, Florida • Buffalo, New York + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Peer Mentoring; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Blood Pressure, Hypertension, Mhealth
Interventions: PACESETTER; Device
Lead sponsor: Northern California Institute of Research and Education; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: San Francisco, California • Charleston, South Carolina • Columbia, South Carolina + 1 more

Conditions: Cataract
Interventions: Dexamethasone Phosphate Ophthalmic, 100 mM Sodium Citrate Buffer; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 3
States / cities: Miami, Florida • Tamarac, Florida • Washington, Missouri

Conditions: Basal Cell Carcinoma
Interventions: Vismodegib, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 13 more

Conditions: Hematopoietic and Lymphatic System Neoplasm
Interventions: SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration; Biological · Procedure · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes (T1D)
Interventions: SAB-142, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 40 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more

Conditions: Cardiovascular Events
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo for Aliskiren, Placebo for Amlodipine, Placebo for Hydrochlorothiazide (HCTZ); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years and older
Enrollment: 2,336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Northridge, California + 11 more

Conditions: Sickle Cell Disease
Interventions: Single Session Problem-Solving Intervention; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 7 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypoplastic Left Heart Syndrome
Interventions: Lomecel-B medicinal signaling cells; Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: Up to 12 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: Tricuspid Valve Insufficiency, Right Heart Failure, Heart Failure
Interventions: Tricuspid valve repair or replacement, Medical management of tricuspid regurgitation; Procedure · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Kidney Disease and Hypertension
Interventions: Baxdrostat/dapagliflozin, Placebo/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 133
States / cities: Fairhope, Alabama • Surprise, Arizona • Tucson, Arizona + 117 more

Conditions: Acetabular Fracture
Interventions: Open Reduction internal Fixation, Open Reduction Internal Fixation with Total Hip Arthroscopy; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years to 100 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Short Bowel Syndrome
Interventions: WHO ORS, Commercial ORS; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Moderated-high Risk of Postoperative Pulmonary Complication, Abdominal Surgery Expected More Than Two Hours
Interventions: Alveolar recruitment maneuver, Calculation of optimal PEEP, Postoperative CPAP; Procedure
Lead sponsor: Fundación para la Investigación del Hospital Clínico de Valencia; Other
Eligibility: 18 Years and older
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Rhinosinusitis (CRS)
Interventions: Patient Centered CRS Treatment Decision Support; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions: PEPRR, Pep-Pal; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 64 Years
Enrollment: 538 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, External Beam Radiation Therapy, Ganitumab, Ifosfamide, Stereotactic Radiosurgery, Therapeutic Surgical Procedure, Vincristine, Vincristine Sulfate; Drug · Radiation · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 50 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 298
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 203 more

Conditions: Infection Control
Interventions: Enhanced cleaning of surfaces in ICU rooms, Sham enhanced cleaning of surfaces in ICU rooms; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin 5mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 15
States / cities: Birmingham, Alabama • Long Beach, California • North Hollywood, California + 12 more

Conditions: Respiratory Failure
Interventions: PAV Ventilation, NAVA Ventilation; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease, Coronary Artery Bypass Graft Surgery
Interventions: neuromuscular electrical stimulation; Device
Lead sponsor: University of Vermont; Other
Eligibility: 50 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Burlington, Vermont

Search by objective public record fields.

Treatment of IPF With Laparoscopic Anti-Reflux Surgery

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control

PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL

A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chronic Transfusion to Treat Sickle Cell Disease

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation Study

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

RCT Determining Best Treatment for Geriatric Acetabular Fractures

Comparison of Different Oral Rehydration Solutions

Individualized Perioperative Open Lung Ventilatory Strategy

Treatment Decision-Making Among Patients With Chronic Rhinosinusitis

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Enhanced Room Cleaning in Intensive Care Units to Reduce Gown and Glove Contamination With Multi-drug-resistant Bacteria

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Impact of PAV Versus NAVA on Patient-Ventilator Synchrony and Respiratory Muscle Unloading

Transitional Rehabilitation in CABG Patients